Pharmaceutical, Biotechnology Industry News

Wed, 15 Oct 2014 15:05:08 -0400

Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE®) antibody construct, blinatumomab. The...

Wed, 15 Oct 2014 15:02:05 -0400

Pfizer Inc. today announced the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA). This NDA requests FDA approval of palbociclib, in...

Mon, 29 Sep 2014 10:16:33 -0400

Digitron – an Elektron Technology brand – has announced new additions to its extensive range of robust hand-held digital thermometers. Demanding industrial and food environments will benefit from the rugged, water resistant 1000 Series...

Mon, 29 Sep 2014 08:23:38 -0400

Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that its Tumor BRACAnalysis CDx™ companion diagnostic test significantly improved the detection of cancer-causing BRCA 1/2 mutations by 44 percent in women with ovarian cancer. Data from this...

Thu, 25 Sep 2014 12:26:17 -0400

Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will host a summary webcast of Kyprolis® (carfilzomib) for Injection data presented at the European Society for Medical Oncology (ESMO) 2014 Congress on...

Tue, 23 Sep 2014 10:24:39 -0400

TV personality, fashion entrepreneur and star of the "Real Housewives of Beverly Hills" Kyle Richards is partnering with Allergan, the makers of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, to raise awareness of Chronic Dry Eye. As many as...

Tue, 23 Sep 2014 10:20:32 -0400

Biogen Idec (NASDAQ:BIIB) has been named the biotechnology industry leader on the Dow Jones Sustainability World Index (DJSI World). The company also was named to the Dow Jones Sustainability Index (DJSI) North America for the fifth consecutive...

Mon, 22 Sep 2014 16:21:18 -0400

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Merck’s investigational once-weekly DPP-4 inhibitor for the...

Pages